This report (IHE Report 2016:9) updates the previous one by evaluating the effects from including DPP-4 inhibitors, GLP-1 agonists and SGLT-2 inhibitors in second-line treatment. This treatment strategy is estimated to reduces the risk of premature death and decrease microvascular and macrovascular complications compared to a strategy similar to current standard of care in Sweden. At the current price level, the total societal cost was estimated to increase due to the use DPP-4 inhibitors, GLP-1 agonists and SGLT-2 inhibitors. When accounting for expected price reduction due to future patent expiries, the total societal cost was instead estimated to decrease by year 2030.
IHE Report 2016:9, IHE: Lund